Novo Nordisk's next-gen obesity drug Cagrisema: investors seek answers
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
Novo Nordisk defends next-gen obesity drug CagriSema, gives details of new trial
Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...
Outsourcing-pharma13d
Novo Nordisk’s next-generation obesity drug shows promise in early clinical trials
Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...
Novo Nordisk cashes in on obesity and diabetes drugs as profits swell
Novo Nordisk reported turnover from obesity treatments soared by 57 per cent to 65.1 billion Danish kroner last year, largely ...
Wegovy sales double to boost Novo Nordisk's fourth quarter as growth set to slow
Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the fourth quarter, ...
Obesity drug sales surge at Novo Nordisk
Sales of Novo Nordisk’s obesity drug, Wegovy, rose by more than 50 per cent last year, helping the Danish drugmaker beat revenue expectations.
FierceBiotech5d
Novo flunks kidney disease trial, again linking obesity prospect to neuropsychiatric side effects
Novo Nordisk’s cannabinoid CB1 receptor blocker has run into another problem. | Novo Nordisk’s cannabinoid CB1 receptor blocker has run into another problem. Months after sharing obesity data that ...
AOL5d
Novo Nordisk defends next-gen obesity drug CagriSema, details new trial
By Maggie Fick and Stine Jacobsen LONDON/COPENHAGEN (Reuters) -Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in ...